Eli Lilly and Company (NYSE:LLY) Stock Price Expected to Rise, HSBC Analyst Says

Key Points

• HSBC has raised its target price for Eli Lilly from $700 to $800, indicating a potential downside of 4.81% from the current price of $840.46.
• The company reported earnings of $6.31 per share, exceeding analysts' expectations, with revenue increasing by 37.6% compared to the same quarter last year.
• Insider trading activity shows that directors have recently purchased shares, indicating confidence in the company, with insiders buying a total of 4,514 shares valued at approximately $2.9 million over the last three months.

Eli Lilly and Company (NYSE:LLY - Get Free Report) had its target price upped by equities researchers at HSBC from $700.00 to $800.00 in a research report issued to clients and investors on Wednesday,MarketScreener reports. HSBC's price target suggests a potential downside of 4.81% from the company's current price.

A number of other equities research analysts have also weighed in on LLY. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Leerink Partners reiterated a "market perform" rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Eli Lilly and Company in a research report on Saturday, September 27th. Finally, Cantor Fitzgerald decreased their price objective on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus target price of $938.94.

Eli Lilly and Company Stock Up 2.5%

LLY stock opened at $840.46 on Wednesday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The firm has a market cap of $795.47 billion, a PE ratio of 54.93, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47. The business has a 50 day moving average of $734.60 and a 200 day moving average of $766.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. During the same period last year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other news, Director J Erik Fyrwald purchased 1,565 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jamere Jackson acquired 200 shares of the company's stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 over the last three months. Corporate insiders own 0.13% of the company's stock.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently added to or reduced their stakes in the stock. Summit Financial Wealth Advisors LLC grew its position in Eli Lilly and Company by 12.5% during the 3rd quarter. Summit Financial Wealth Advisors LLC now owns 1,218 shares of the company's stock worth $1,005,000 after purchasing an additional 135 shares during the last quarter. Aaron Wealth Advisors LLC raised its stake in Eli Lilly and Company by 78.3% in the 3rd quarter. Aaron Wealth Advisors LLC now owns 10,003 shares of the company's stock worth $7,632,000 after acquiring an additional 4,392 shares during the last quarter. St. Clair Advisors LLC purchased a new stake in Eli Lilly and Company during the 3rd quarter valued at about $835,000. IMPACTfolio LLC acquired a new position in shares of Eli Lilly and Company in the third quarter valued at about $306,000. Finally, Central Pacific Bank Trust Division raised its stake in shares of Eli Lilly and Company by 25.8% in the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company's stock worth $6,859,000 after purchasing an additional 1,843 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.